Nancy U. Lin, MD

Drs Camidge and Lin discussed Dr Lin's work with brain metastases and her role in developing targeted therapies for breast cancer.

Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.

Nancy U. Lin, MD, discusses the importance of the DESTINY-Breast12 trial of T-DXd in patients with HER2+ breast cancer with vs without brain metastases.

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

Nancy U. Lin, MD, discusses selecting between systemic vs local therapy for patients with HER2-positive breast cancer displaying central nervous system metastases.

Nancy U. Lin, MD, discusses the advantage of the oral selective estrogen receptor degrader, elacestrant, in ESR1-mutated breast cancers.

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.

Nancy U. Lin, MD, discusses updated findings from the phase 2 HER2CLIMB study in patients with HER2-positive metastatic breast cancer with brain metastases.

Nancy U. Lin, MD, discusses central nervous system activity with HER2-directed TKIs in HER2-positive breast cancer.